Skip to main content
Clinical Trials/NCT00603824
NCT00603824WithdrawnPhase 4

Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia

Methodist Healthcare0 sitesStarted: January 2008Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Withdrawn
Primary Endpoint
Platelet count recovery

Study Overview

Brief Summary

The purpose of this study is to test the safety and efficacy of fondaparinux in patients with heparin-induced thrombocytopenia (HIT). The primary objective is to ensure that patients with HIT who are treated with fondaparinux experience a prompt and complete recovery of their platelet count, and the secondary objective is to determine if any new blood clots are formed while receiving the fondaparinux and up to one month after study enrollment. This information will be compared to a historical control.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or female at least 18 years of age;
  • If female of childbearing potential, negative pregnancy test result;
  • Diagnosis of HIT confirmed by the following: Decreased platelet count by 50% or greater OR platelets < 100,000/mm3 during or within 2 weeks after heparin exposure and/or new thromboembolic complications during or within 2 weeks after heparin exposure;
  • Laboratory confirmation (either heparin PF4 antibody or serotonin release assay positive).

Exclusion Criteria

  • Estimated creatinine clearance less than 30 ml/min (either measured or by using Cockcroft Gault equation);
  • Pregnancy or lactating;
  • Blood dyscrasia other than HIT;
  • History of thrombocytopenia associated with fondaparinux;
  • Recent (within 6 weeks) or planned surgery of CNS, eye or traumatic surgery resulting in large open surfaces or other procedures with high bleeding risk or if lumbar puncture is planned;
  • Active bleeding of GI tract, GU tract, CNS or respiratory tract;
  • Malignant hypertension, pericarditis, pericardial effusion, endocarditis or eclampsia;
  • Inadequate laboratory facilities, inadequate support system at home, alcoholism, drug abuse, psychosis or dementia;
  • Hypersensitivity or contraindication to warfarin or fondaparinux.

Arms & Interventions

A

Experimental

Fondaparinux

Intervention: fondaparinux (Drug)

B

Active Comparator

Direct thrombin inhibitor

Intervention: argatroban or lepirudin (Drug)

Outcomes

Primary Outcomes

Platelet count recovery

Time Frame: 5 days

Secondary Outcomes

  • Recurrent thromboembolic complications(4 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials